Eric L. Smith, MD, PhD
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated responses in various hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (ALL).
at the 2017 European Hematology Association Congress, Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discussed the response to CD19 CAR T-cell therapy in B-cell ALL.
OncLive: Could you please provide an overview of this study?
: We, like other institutions, take a patient’s own T cells and then we engineer into those T cells a gene that on the outside has an antibody fragment that attracts the T cell to the CD19 molecule. Outside the T cell there are stimulatory signals that cause the T cell to both kill and also, equally important, to divide.
... to read the full story